TG Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 30 U.S.-traded ETFs. TGTX has around 6.5M shares in the U.S. ETF market. The largest ETF holder of TGTX is the SPDR S&P Biotech ETF (XBI), with approximately 2.30M shares. Investors may also find of interest that the ETF with the largest allocation to TGTX stock is Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a portfolio weight of 0.97%. On average, U.S. ETFs allocate 0.11% of TGTX to their portfolios.
Additionally, TGTX is a favorite stock for Vanilla and Equal ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with TGTX as a holding is the Principal Healthcare Innovators Index ETF (BTEC), with a return of 17.23%.